|
|
|
08.06.26 - 17:18
|
Campbell′s Earnings Beat; Eli Lilly Obesity Drug Results | Stock Movers (Bloomberg)
|
|
|
On this episode of Stock Movers with Alexis Christoforous:
- Shares of The Campbell's Company (CPB) edged higher ahead of the US market open after the canned soup maker reported adjusted earnings per share for the third quarter that beat the average analyst estimate.
- Eli Lilly (LLY) shares gained in the early session following obesity drug presentations at the American Diabetes Association conference. Citi analysts say their conviction on Lilly is firmly intact, given the company's incretin portfolio is “not built around singular blockbusters.”
- Shares of Marvell Technology (MRVL) and Flex (FLEX) are rising in premarket trading as the companies are set to replace Pool Corp. and Campbell's in S&P 500 before the market open on June 22, S&P Dow Jones Indices says in emailed statement. (Source: Bloomberg)...
|
|
|
|
|
21.05.26 - 18:03
|
Lilly′s Next-Gen Weight-Loss Drug Clears Trial With Near-Bariatric Surgery Results (ZeroHedge)
|
|
|
Lilly's Next-Gen Weight-Loss Drug Clears Trial With Near-Bariatric Surgery Results
Eli Lilly reported positive Phase 3 results for its next-generation obesity drug, retatrutide, which delivered weight-loss results on par with those of bariatric surgery.
In the TRIUMPH-1 trial, overweight adults, but without diabetes, achieved meaningful weight loss across all tested doses after 80 weeks:
12 mg dose: average weight loss of 70.3 pounds, or 28.3% of body weight.
9 mg dose: average weight loss of 64.4 pounds, or 25.9%.
4 mg dose: average weight loss of 47.2 pounds, or 19%
Ahead of the results, RBC Capital Markets analyst Trung Huynh said the key success range would be 28% to 30% weight loss.
Lilly's 12 mg dose appears to have cleared the low end of Huynh's bar, with patients losing an average of 28.3% of their body weight over 80 weeks.
"We're in a zone that's historically been associated with bariatric surgery, and you're getting it with a medicine," Kenneth Custer, ...
|
|
|
12.05.26 - 14:33
|
HIMS Shares Plunge As Pivot To Branded GLP-1s Weighs On Outlook (ZeroHedge)
|
|
|
HIMS Shares Plunge As Pivot To Branded GLP-1s Weighs On Outlook
Hims & Hers shares tumbled in premarket trading in New York, the most in three months, after the company posted a first-quarter loss and revenue that missed analyst estimates tracked by Bloomberg, as costs rose amid a massive pivot from selling copycat GLP-1 drugs toward branded obesity drugs from Novo Nordisk and Eli Lilly.
Revenue for the first quarter came in at $608 million versus the $617.5 million Bloomberg Consensus estimate, while the telehealth firm swung to a loss of 40 cents a share from a 20-cent profit a year earlier.
HIMS recorded $33.5 million in restructuring charges, including inventory write-downs and transition costs.
"This was an incredibly valuable transition," HIMS CEO Andrew Dudum told analysts on an earnings call. "We are seeing adoption and weight-loss near-record levels, even beyond the demand we saw following this year's New Year's and Super Bowl campaigns."
Here's a snapshot o...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
09.04.26 - 09:31
|
India′s Generic Copies Dent Eli Lilly′s Sales (Bloomberg)
|
|
|
The flood of cheap copies of Novo Nordisk A/S' blockbuster drug semaglutide in India is already reshaping the country's fast-growing obesity market, cutting into Eli Lilly & Co.'s early lead and offering a first real test of how Novo may fare as its patents expire worldwide....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
